Suit Over Novartis Drug’s Bone Death Risk Heads To Jury

Law360, New York (May 14, 2013, 7:56 PM EDT) -- After 11 days of testimony from some 20 witnesses, jurors began deliberating Tuesday in the New Jersey mass tort lawsuit of a woman suing Novartis Pharmaceuticals Corp. for allegedly minimizing the risks of bone death in the jaw from its bone-strengthening drug Zometa.

Attorneys for plaintiff Beverly Meng said during closing arguments in New Jersey state court that internal Novartis emails show the company was more concerned about profits than providing oncologists with responsible warnings about links between osteonecrosis of the jaw, or ONJ, and bisphosphonates...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.